(Report) Seminar “Solution for Global Health Issues -Public and Private Partnership-“
date : 11/5/2013
In recent years, there has been rapid economic growth in some developing countries which is seen as a new market opportunity for businesses, however, these
countries are disadvantaged by their limited access to medical resources. In particular they are significantly handicapped by the three major infectious
diseases i.e. HIV/AIDS, Tuberculosis, Malaria, and NTD (Neglected Tropical Diseases).
As public funding is limited, an innovative business model called “Public-Private-Partnership”(PPP) plays an important role in solving global health issues
in developing countries. PPP is a government service or private business venture which is funded and operated through a partnership of government and one or
more private sector companies.
In the first session of the current sequential seminars, we would like to hold discussion about why PPP has drawn great attention especially in the global
health field. By introducing examples of PPP by The Global Health Innovative Technology Fund (GHIT Fund,) which aims to solve global health issues, we
discussed how government and private sector companies can cooperate and maximize the partnership. The GHIT Fund is a non-profit organization aimed at
promoting the discovery and development of new health technologies including drugs, vaccines and diagnostics for infectious diseases prevalent in developing
counties.The first partnership of its kind in Japan, the GHIT Fund is a PPP established by the Government of Japan, a consortium of Japanese pharmaceutical
companies and the Bill & Melinda Gates Foundation in 2012. Through the session, we discussed and explored sustainable ways of contributing to global health
solutions with speakers and audience participation.
*Language: Japanese
■Date and Time
Oct 23, 2013 19:00-21:00
■Venue
ARK HILLS Club
37F East Wing, ARK Mori Building,
1-12-32 Akasaka, Minato-ku, Tokyo
■Theme
“Global Health and Public-Private Partnership”
■Speaker
-Kiyoshi Kurokawa
Professor, National Graduate Institute for Policy Studies / Chairman, Health and Global Policy Institute / Chair of the Board & Representative Director,
Global Health Innovative Technology Fund
-Kei Katsuno
Derector of Strategy, Global Health Innovative Technology Fund
■Fee
1,500 Yen (Student 1,000yen(Please show your school identification card.))
■Application Procedure
Please complete the online procedure on the Health and Global Policy Institute website by noon on Monday, Oct 21th, 2013. When the seats are fully booked,
we may stop accepting applications.
■Organizer
Health and Global Policy Institute
Since its establishment in 2004, the Health and Global Policy Institute (HGPI) has been working to help interested citizens shape health policies by
generating policy options and bringing stakeholders together as a nonpartisan think tank. HGPI’s mission is to improve civic and individual well-being and
to foster as sustainable healthy community by shaping ideas and values, reaching out to global needs, and catalyzing society for impact. HGPI commits to
activities that bring together relevant players in different fields to provide innovative and practical solutions and help interested citizens understand
choices and benefits in a global, long-term perspective. HGPI promotes a Global Citizen Nation by building a society for people with various backgrounds and
different values. It aims to achieve a sustainable, healthy, and more prosperous world.
Global Health Innovative Technology Fund
The Global Health Innovative Technology Fund (GHIT Fund) is Japan’s first public-private partnership to advance the development of new health technologies
for the developing world.
The first product development fund of its kind in Japan, the GHIT Fund was created by the Japanese Government, Japan’s leading pharmaceutical companies, and
the Bill & Melinda Gates Foundation.
The GHIT Fund is bringing Japanese leadership in health and technology innovation from its public and private sectors to the global fight against infectious
diseases. The goals is to facilitate and fund
global health R&D partnerships that can generate new drugs, vaccines and diagnostics and other tools for fighting neglected diseases prevalent in developing
world.
■Cooperated with
MORI HOSPITALITY CORPORATION
■Secretariat
Health and Global Policy Institute
Tel: 03-5511-8521
Email: info@hgpi.org
countries are disadvantaged by their limited access to medical resources. In particular they are significantly handicapped by the three major infectious
diseases i.e. HIV/AIDS, Tuberculosis, Malaria, and NTD (Neglected Tropical Diseases).
As public funding is limited, an innovative business model called “Public-Private-Partnership”(PPP) plays an important role in solving global health issues
in developing countries. PPP is a government service or private business venture which is funded and operated through a partnership of government and one or
more private sector companies.
In the first session of the current sequential seminars, we would like to hold discussion about why PPP has drawn great attention especially in the global
health field. By introducing examples of PPP by The Global Health Innovative Technology Fund (GHIT Fund,) which aims to solve global health issues, we
discussed how government and private sector companies can cooperate and maximize the partnership. The GHIT Fund is a non-profit organization aimed at
promoting the discovery and development of new health technologies including drugs, vaccines and diagnostics for infectious diseases prevalent in developing
counties.The first partnership of its kind in Japan, the GHIT Fund is a PPP established by the Government of Japan, a consortium of Japanese pharmaceutical
companies and the Bill & Melinda Gates Foundation in 2012. Through the session, we discussed and explored sustainable ways of contributing to global health
solutions with speakers and audience participation.
*Language: Japanese
■Date and Time
Oct 23, 2013 19:00-21:00
■Venue
ARK HILLS Club
37F East Wing, ARK Mori Building,
1-12-32 Akasaka, Minato-ku, Tokyo
■Theme
“Global Health and Public-Private Partnership”
■Speaker
-Kiyoshi Kurokawa
Professor, National Graduate Institute for Policy Studies / Chairman, Health and Global Policy Institute / Chair of the Board & Representative Director,
Global Health Innovative Technology Fund
-Kei Katsuno
Derector of Strategy, Global Health Innovative Technology Fund
■Fee
1,500 Yen (Student 1,000yen(Please show your school identification card.))
■Application Procedure
Please complete the online procedure on the Health and Global Policy Institute website by noon on Monday, Oct 21th, 2013. When the seats are fully booked,
we may stop accepting applications.
■Organizer
Health and Global Policy Institute
Since its establishment in 2004, the Health and Global Policy Institute (HGPI) has been working to help interested citizens shape health policies by
generating policy options and bringing stakeholders together as a nonpartisan think tank. HGPI’s mission is to improve civic and individual well-being and
to foster as sustainable healthy community by shaping ideas and values, reaching out to global needs, and catalyzing society for impact. HGPI commits to
activities that bring together relevant players in different fields to provide innovative and practical solutions and help interested citizens understand
choices and benefits in a global, long-term perspective. HGPI promotes a Global Citizen Nation by building a society for people with various backgrounds and
different values. It aims to achieve a sustainable, healthy, and more prosperous world.
Global Health Innovative Technology Fund
The Global Health Innovative Technology Fund (GHIT Fund) is Japan’s first public-private partnership to advance the development of new health technologies
for the developing world.
The first product development fund of its kind in Japan, the GHIT Fund was created by the Japanese Government, Japan’s leading pharmaceutical companies, and
the Bill & Melinda Gates Foundation.
The GHIT Fund is bringing Japanese leadership in health and technology innovation from its public and private sectors to the global fight against infectious
diseases. The goals is to facilitate and fund
global health R&D partnerships that can generate new drugs, vaccines and diagnostics and other tools for fighting neglected diseases prevalent in developing
world.
■Cooperated with
MORI HOSPITALITY CORPORATION
■Secretariat
Health and Global Policy Institute
Tel: 03-5511-8521
Email: info@hgpi.org
Exhibition date：2013-10-23
Top Research & Recommendations Posts
- [Publication Report] Planetary Health Promotion Project “Issues Facing Planetary Health and the Role of the Health Sector” (May 10, 2023)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022）
- [Policy Recommendations] Building a Research and Development System Together With People Living with Dementia and Their Families to Drive Parallel Progress in Creating an Inclusive Society and Advancing R&D (April 25, 2023)
- [Public Comment Submission] Opinions Regarding the Proposed “National Action Plan on Antimicrobial Resistance 2023-2027 (Draft)” (March 16, 2023)
- [Recommendations] Recommendations for the G7 Hiroshima Summit in 2023 Necessary Actions for AMR Control, Starting with the Introduction of Pull Incentives (August 29, 2022)
- [Policy Recommendations] Recommendations for the G7 Hiroshima Summit by the C7 Global Health Working Group (April 20, 2023)
- [Policy Recommendations] Requests for the G7 Hiroshima Summit and Related Ministerial Meetings: Promoting Measures for Climate Change and Planetary Health That Keep Pace With the International Community (December 19, 2022)
- [Research Report] The Public Opinion Survey on Mental Health (August 12, 2022)
- [Recommendations] Restructuring Diagnostic Services and Achieving the Necessary Innovation to Promote AMR Control (May 26, 2023)
Featured Posts
-
2023-05-12
[Event Report] Recommendations to Prime Minister Fumio Kishida on the issue of antimicrobial resistance (AMR) in the G7 Hiroshima Summit Leaders’ Declaration (April 28, 2023)
![[Event Report] Recommendations to Prime Minister Fumio Kishida on the issue of antimicrobial resistance (AMR) in the G7 Hiroshima Summit Leaders’ Declaration (April 28, 2023)](https://hgpi.org/en/wp-content/uploads/sites/2/amr-20230428-top2-scaled.jpg)
-
2023-05-15
[Event Report] (Live Broadcasting) A Dementia Symposium Commemorating the G7 Health Ministers’ Meeting in Nagasaki “Collaboration in the International Community for Advancing Dementia Measures in a New Era” (May 14, 2023)
![[Event Report] (Live Broadcasting) A Dementia Symposium Commemorating the G7 Health Ministers’ Meeting in Nagasaki “Collaboration in the International Community for Advancing Dementia Measures in a New Era” (May 14, 2023)](https://hgpi.org/en/wp-content/uploads/sites/2/g7nagasaki_20230515-1.jpg)
-
2023-05-18
[Event Report] A NAGASAKI Planetary Health Expert Meeting “From COP27 and COP15 to the G7 Hiroshima Summit: New Partnerships for Solving Climate, Environment, Biodiversity and Health Issues” (May 12, 2023)
![[Event Report] A NAGASAKI Planetary Health Expert Meeting “From COP27 and COP15 to the G7 Hiroshima Summit: New Partnerships for Solving Climate, Environment, Biodiversity and Health Issues” (May 12, 2023)](https://hgpi.org/en/wp-content/uploads/sites/2/nagasakiglobalexpertmeeting-1-top.jpg)
-
2023-05-19
[RegistrationOpen] Health Policy Academy the 12th Session
![[RegistrationOpen] Health Policy Academy the 12th Session](https://hgpi.org/en/wp-content/uploads/sites/2/hpa12-top.png)
-
2023-05-26
[Recommendations] Restructuring Diagnostic Services and Achieving the Necessary Innovation to Promote AMR Control (May 26, 2023)
![[Recommendations] Restructuring Diagnostic Services and Achieving the Necessary Innovation to Promote AMR Control (May 26, 2023)](https://hgpi.org/en/wp-content/uploads/sites/2/amr-20230526-top_ENG.png)
